Twitter

New analysis from Västra Hamnen after the completion of the rights issue

Västra Hamnen have released a new analysis of Chordate Medical, as a result of the comapny’s Q3 report from November and the recently completed rights issue.

“The positive study results represent an important step in the process towards an exit”, Västra Hamnen in the analysis.

Västra Hamnen further write:

“Chordate’s report for the third quarter was characterized by positive study results from the migraine study (PM007). The results support the company’s scientific evidence and the focus will now be on the company’s commercial proof of concept. During the quarter, the company commenced a market introduction in Finland and participated in five international neurology congresses. We increase the probability of an exit, which in turn increases the value of the company, but due to dilution from the rights issue, the corresponding valuation range is reduced to SEK 1.46 – 2.17 from the previous SEK 1.70 – 2.70 per share.”

Västra Hamnen Corporate Finance is Chordate’s Certified Adviser, you can find the full analysis here (in Swedish).

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter